Kornimate/medical-research-clean huggingface dataset:
examining the longitudinal relationship between sleep and weight gain in college students

Conditions: Healthy; Overweight

Summary: this two-year prospective, observational study examines the relationship between habitual short sleep and weight gain, as well as the association between habitual short sleep and behaviors that put people at risk of weight gain. habitual short sleep is defined as sleeping \<6 hours per night on average. participants will be healthy freshmen college students who are normal weight or overweight. exclusion criteria include pregnancy, an inability to be ambulatory, currently taking a medication that could influence or interfere with sleep, or reporting a past/current neurological problem, past/current head injury, past/current sleep disorder, current mood, anxiety, or substance use disorder, current psychosis, or current suicidal ideation/plans. recruitment will be during new student orientations that occur prior to fall semester. eligibility will be determined using a screening interview, the dsm-5 self-rated level 1 cross-cutting symptom measure - adult, and dsm-5 self-rated level 2 measures. eligible participants will be assessed at baseline (time 1), and 8, 16, and 24 months after time 1. sleep, physical activity, food/beverages, substance use, and technology use will be collected daily during each eight day recording period. sleep will be measured with a sleep monitor, activity will be assessed using an accelerometer, food/beverages will be obtained using the national cancer institute's automated self-administered 24-hour dietary assessment tool, and substance use and technology use will be measured via self-report. participants will attend a session after each recording period to have weight and height measured, be scanned via dual-energy x-ray absorptiometry (dxa), and complete a packet of questionnaires about demographics, health, sleep quality and beliefs, life events, food cravings, and physical development. it is hypothesized that participants will have different habitual sleep trajectories over time. it is also hypothesized that two particular sleep trajectories (stable habitual short sleep and increasingly shorter habitual sleep across time) will be significantly related to weight gain, increased body fat percent, and weight gain risk behaviors (i.e., increased caloric intake and decreased physical activity). finally, it is hypothesized that the two sleep trajectories will be significantly associated with higher rates of media and technology use and higher rates of problematic sleep-related beliefs/behaviors.


Eligibility criteria:
inclusion criteria: * college freshmen * traditional college age * bmi from 18.5-29.9. exclusion criteria: * neurological problem * head injury * sleep disorder * mood disorder * anxiety disorder * substance use disorder * psychosis * suicidal ideation/plan * lacking the ability to be ambulatory * pregnancy

Keywords: sleep obesity body fat composition young adults diet activity dual x-ray absorptiometry
biobanking for biomarkers in respiratory disease, allergic diseases and/or mast cell disorders

Conditions: Allergic Diseases; Asthma; Mast Cell Disorders

Summary: this study aims to build up a clinico-biological bank of samples from patients suspected of or suffering from allergic diseases (including asthma) or mast cell diseases in order to support future research in the field of allergic diseases. the biobank will help to identify new prognostic, diagnostic and/or predictive biomarkers.

this is a prospective monocentric collection of biological samples combined with clinical and paraclinical data from patients suffering from allergic diseases, asthma or mast cell disorders. the aim of this collection is to collect biological samples and clinical data to be used for various exploratory, diagnostic and/or prospective and/or predictive studies. the samples and data will be pseudonymised, i.e. identified by the first letter of the patient's surname and first name and by a number allocated in chronological order of patient inclusion, and will be stored in a bank. the samples and data making up this clinico-biological bank will be used for subsequent exploratory work used as a priority to answer questions from the toulouse university hospital teams in the field of allergic diseases, asthma and/or mast cell disorders, in accordance with the information given to the patient. they may also be transferred to specialised research teams as part of national or international collaborations, or sold to academic or industrial partners. these transfers as part of collaborations or assignments will be legally governed by contracts guaranteeing compliance with the rgpd, where applicable, and the use of these samples in accordance with current legislation and the information provided to patients.

Eligibility criteria:
inclusion criteria: * patients with a positive prick test or specific ige regardless of the allergen * patients suspected of allergic pathology defined by the need to carry out a prick test or specific ige or a food or drug reintroduction test as part of the treatment * patients with systemic or cutaneous mastocytosis according to the international classification8 * patients with mast cell activation syndrome according to the international classification8 * patients with familial hyper-alpha tryptasemia on the presence of variation in the number of copies of the alpha allele of the tpsab1 gene * patients with asthma of any severity * people affiliated or beneficiaries of a social security scheme * patients able to receive and understand the information on the study and their participation and having freely consented to it in writing before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and mastery of the french language). exclusion criteria: * patients under legal protection, guardianship or curatorship * pregnant or breastfeeding women

Keywords: allergy asthma mast cell disorders biomarkers biobank
prehabilitation in pancreatic surgery

Conditions: Pancreatic Resection; Preoperative Frailty

Summary: the purpose of this study is to use functional studies to study the effectiveness of prehabilitation prior to surgery. the investigators know that stronger patients have better outcomes after surgery compared to weaker patients. this study will help the study team determine if prehabilitation can make patients stronger prior to surgery. it is hoped by learning more about frailty and prehabilitation strategies may be developed to minimize or prevent complications in the future. participants are being asked to participate in this study because they are going to have a pancreatic procedure.

this study aims to determine if a prehabilitation program can improve three objective frailty metrics and to describe the level of physical activity of pancreatectomy patients prior to their planned resection. patients undergoing pancreatectomy will undergo routine preoperative work up: staging pet/ct chest/abdomen/pelvis, and biochemical work up (cbc, cmp, ca 19-9, prealbumin/albumin). during the initial consultation, the patients' resting vitals (including weight) will be recorded. they will then perform the grip strength, 30s cst, and 6mwt to establish their baseline frailty metrics. available baseline laboratory values (cbc, cmp including albumin), will also be recorded. research personnel will then provide them with a fitness tracker, stress ball, and prehabilitation routine to follow at home until the day of surgery. they will also be asked to keep a physical log of their completed physical activities. the patients will then complete the prehabilitation program during the time between the initial consultation and date of surgery, which typically occurs 3-4 weeks after the initial consultation date. on the day of surgery, patients will turn in their physical log and their fitness tracker. data from the fitness tracker will be downloaded onto a cleveland clinic encrypted computer. a set of resting vitals will be recorded (again including weight) and the patients will then be asked to perform the three-frailty metrics (grip strength, 30s cst, and 6mwt). after this, the patients will not require any additional testing.

Eligibility criteria:
inclusion criteria: * undergoing pancreatic resection over a six-month enrollment exclusion criteria: * unable to sign a consent * require a translator in order to sign the consent * non-pancreatic resection candidates
gastrointestinal microbiome influence on the development of bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: the purpose of this study is to advance our knowledge of the factors that contribute to the development of bronchopulmonary dysplasia (bpd), a chronic lung affecting premature infants. specifically, the investigators will determine the complexity of the gut microbiota, the genera of the bacteria that naturally live in the gut, and determine if the relative diversity of the gut bacteria is a prognostic indicator of bpd. to accomplish this, the investigators propose to characterize the microbiota of human premature newborns with bpd, then validate this potential mechanism in mice. the investigators will enroll very low birthweight premature infants admitted to the neonatal intensive care units (nicu) at le bonheur children's hospital and regional one health that are at high risk to develop bpd. a cohort of well full term newborns will also be enrolled. non-invasive stool samples will be obtained weekly over the first month of life. infants that eventually develop bpd will be paired with infants that did not develop bpd. stool samples from these infants will be sent for analysis. the investigators expect that reduced complexity of the gut microbiome is associated with bpd. the investigators will model the contribution of reduced microbiome complexity to the risk to develop bpd or death, as well as the association with disease severity. the project investigates important factors leading to the development of bpd, and has the potential to directly translate to therapy for the most significant pulmonary complication of prematurity.


Eligibility criteria:
inclusion criteria: 1. newborn humans less than 1 week of age with a birthweight less than 1,500 g, or fetuses with impending delivery and estimated birthweight of less than 1,500 grams. no individuals will be excluded on the basis of sex or ethnicity. 2. parents can understand and comply with planned study procedures. 3. parents provide assent/permission prior to any study procedures. inclusion criteria mothers: 1. the mother's of infants meeting the infant inclusion criteria above. exclusion criteria: 1. diagnosed immunodeficiency disorder. 2. currently receiving investigational immunomodulatory, probiotic or antiviral agent. 3. infants whose mothers meet the exclusion criteria below. exclusion criteria mothers: 1. diagnosed immunodeficiency disorder 2. currently receiving investigational immunomodulatory, probiotic or antiviral agents 3. lacking the mental capacity (e.g. due to pain, anesthesia, mental impairment) to provide informed consent for themselves or assent for the participation of their infant. 4. having an infant that meets the infant exclusion criteria.

Keywords: bronchopulmonary dysplasia microbiome microbiota premature infant observational cohort study
tace with lenvatinib versus lenvatinib alone in in first-line treatment of advanced hcc

Conditions: Advanced Hepatocellular Carcinoma

Summary: this trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. the purpose is to compare the efficacy and safety of lenvatinib plus tace with lenvatinib alone for advanced hcc patients.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years old; 2. patients with primary advanced hcc (in accordance with aasld2018 guidelines for the diagnosis of hcc), without any previous treatment; 3. there is at least one measurable lesion in the liver according to mrecist criteria, single tumor ≤ 10.0 cm or multiple tumors and tumor burden ≤50% , with portal vein tumor embolus or with extrahepatic metastasis; 4. ecog score 0-1; 5. child-pugh class a; 6. expected survival time ≥ 3 months; 7. blood, liver and kidney function meet the following conditions: neutrophil count ≥ 1.5 × 10 9 /l; platelet count ≥ 60 × 10 9 /l; hemoglobin ≥ 90 g/l; serum albumin ≥ 30 g/l; bilirubin ≤ 50 umol/l; ast, alt ≤ 5 times the upper limit of normal, alp ≤ 4 times the upper limit of normal; prolongation of prothrombin time not to exceed the upper limit of normal by 6 seconds; creatinine ≤ 1.5 times the upper limit of normal exclusion criteria: 1. preoperative imaging examination revealed diffuse intrahepatic lesions or invasion, inferior vena cava or primary branch bile duct; 2. previous history of hepatic encephalopathy, refractory ascites or gastric esophageal varices; 3. there are contraindications to tace treatment, such as portosystemic shunt, liver flow ablation, significant atherosclerosis; 4. brain metastases; 5. hypersensitivity to intravenous contrast agents; 6. pregnant or lactating women or subjects with family planning within two years; 7. with hiv, syphilis infection; 8. accompanied by other malignant tumors or suffering from other malignancies within 5 years before enrollment; 9. allogeneic organ transplant recipients; 10. severe dysfunction of heart and kidney or other organs; 11. active severe infection \> grade 2 (nci-ctc version 4); 12. suffering from mental and psychological diseases may affect informed consent; 13. unable to take oral medication; 14. participated in other drug clinical trials within 12 months before enrollment;

Keywords: lenvatinib transarterial chemoembolisation
influence of respiratory and exercise therapy on oxygen uptake, quality of life and right ventricular function in severe pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: aim of this study is to investigate whether and to what extent a cautious respiratory and exercise therapy can complement medical treatment and change the condition, oxygen uptake, quality of life, the pulmonary vascular pressures, the size of the right heart and the 6-minute walk distance in patients with pulmonary hypertension.


Eligibility criteria:
inclusion criteria: * consent form * men and women\> 18 years \<75 years * invasively confirmed chronic ph who have received complete diagnostic evaluation by specialized doctors / physicians according to the who classification at a center for pulmonary hypertension and were adjusted for 2 months under intensive medical therapy and are stable. exclusion criteria: * pregnancy or lactation * change in medication during the last 2 months * patients with signs of right heart decompensation * severe walking disturbance * uncertain diagnoses * no previous invasively confirmation of ph * acute diseases, infections, fever * serious lung disease with fev1 \<50% or tlc \<70% of target * further exclusion criteria are the following diseases: active myocarditis, unstable angina pectoris, exercise-induced ventricular arrhythmias, congestive heart failure, significant heart disease, pacemakers, and hypertrophic obstructive cardiomyopathy, or a highly reduced left ventricular function

Keywords: respiratory therapy exercise therapy oxygen uptake quality of life right ventricular function severe pulmonary hypertension
pre-exposure prophylaxis for sars-coronavirus-2

Conditions: COVID-19; Corona Virus Infection; ARDS; Acute Respiratory Distress Syndrome

Summary: objective: to determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of covid-19 disease.

the current standard of care is observation and quarantine after exposure to covid-19. there is no approved treatment or prophylaxis for covid-19. as of march 6, 2020, the cdc estimates that the transmission of sars-cov2 after a u.s. household close contract is 10.5% (95%ci, 2.9 to 31.4%). among all close contacts, the sars-cov2 transmission rate is estimated at 0.45% (95%ci, 0.12 to 1.6%) by the cdc. these estimates are based on monitoring of travel-associated covid19 cases. conversely, in a setting with community transmission, the secondary attack rate in china was 35% (95%ci, 27-44%) based on 48 transmissions among 137 persons in 9 index patients. chloroquine or hydroxychloroquine may have antiviral effects against sars-cov2 which may prevent covid-19 disease or reduce disease severity. it is not known at what dosing hydroxychloroquine may be effective for pre-exposure prophylaxis.

Eligibility criteria:
inclusion criteria: - a healthcare worker at high risk for covid-19 exposure (defined below): * persons primarily working in emergency departments (physicians, nurses, ancillary staff, triage personnel) * persons primarily working in intensive care units (physicians, nurses, ancillary staff, respiratory therapists) * persons performing aerosol generating procedures (i.e. anesthesiologists, nurse anesthetists (crnas) * first responders (i.e. emts, paramedics) exclusion criteria: * active covid-19 disease * prior covid-19 disease * current fever, cough, shortness of breath * allergy to chloroquine or hydroxychloroquine * prior retinal eye disease * known chronic kidney disease, stage 4 or 5 or dialysis * known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency * weight \<40 kg * prolonged qt syndrome * current use of hydroxychloroquine, chloroquine, or cardiac medicines of flecainide, amiodarone, digoxin, procainamide, or propafenone * current use of medications with known significant drug-drug interactions: artemether, lumefantrine, mefloquine, tamoxifen, or methotrexate.
kimel family centre for brain health and wellness

Conditions: Prevention; Dementia

Summary: participants (n=450; aged 50+; without a diagnosis of dementia; sufficiently fluent in english to complete the assessments and engage in programming) receive a comprehensive dementia risk assessment, including nonmodifiable and modifiable risk factors, from which they receive a personalized dementia risk report and program strategy, indicating their health conditions increasing and their risk level in five modifiable risk domains: physical activity, brain- healthy eating, cognitive engagement, social connections, and mental wellbeing. equipped with this information, participants enroll in programs within the centre to address their risk factors. changes to their dementia risk, cognition, and personalized program strategy are communicated through re-assessments of risk factors every six months (risk and cognition) and every year (comprehensive assessment).

participants (n=450; aged 50+; without a diagnosis of dementia; sufficiently fluent in english to complete the assessments and engage in programming) complete a baseline assessment consisting of three parts. a biosample session in which blood is drawn to measure hba1c, cholesterols, thyroid levels, c-reactive protein, interleukin-6, homocysteine, and bdnf, and a saliva sample is provided to provide a polygenic risk score for ad. a questionnaire session is completed on a tablet or from home asks about demographics, health conditions, and five targeted modifiable factors: physical activity, brain-healthy eating, cognitive engagement, social connections, and mental wellbeing. a clinical session measures vitals, sensory function, frailty markers (grip strength, dxa, ultrasound of right quadriceps muscle), dual-task gait, and cognition (moca and cogniciti's brain health assessment). from that assessment, participants receive a personalized dementia risk report and program strategy, outlining conditions that are known to increase dementia risk, with resources provided on how to get them addressed, as well as their risk level in the five targeted domains. participants then take a smart goal setting workshop to identify smart goals addressing their dementia risk factors, and then sign up for programming in the centre to reduce their risk. after six months, their risk in the five targeted domains, cognition (brain health assessment), and satisfaction are re-assessed, and every year, most of the baseline assessment is repeated. we expect that this personalized approach will result in reductions in risk in the five targeted domains within the first six months, improvements in health factors within the first year, and improvements in cognition within two years.

Eligibility criteria:
inclusion criteria: * aged 50 years or older * sufficiently fluent in english to complete the assessments and participate in programming. exclusion criteria: * diagnosis of dementia.

Keywords: personalized dementia prevention lifestyle factors
acute kidney injury as a risk factor for myocardial injury after non cardiac surgery

Conditions: Acute Kidney Injury (AKI)

Summary: the incidence of acute kidney injury (aki) postoperatively has been identified to be 21.6% in adults and 18.3% in hospitalized individuals. surgery-related aki is a severe complication that is related not only to short-term complications as increases in mortality rate and development of cardiac complications but also with complications on long term, such as development of chronic kidney disease. a better understanding of the mechanism of this hypthesis will lead to better management of this complication.

a randomized blinded prospective study included 206patients who the candidate for major surgery at south egypt cancer institute, assiut university, assiut, egypt. from april 2018 till april 2019, a detailed history and careful examination, routine laboratory investigations were done, baseline ecg was recorded 24hours before surgery and 48hours postoperative at icu.

Eligibility criteria:
inclusion criteria: * patients who were candidates for major non cardiac surgery exclusion criteria: * chronic cardiac diseases (myocardial ischemia, heart failure), active severe infection, pregnancy, chronic kidney disease
efficacy of tak-438 compared to ag-1749 (lansoprazole) in the maintenance treatment of healed erosive esophagitis

Conditions: Erosive Esophagitis

Summary: the purpose of this study is to confirm the efficacy of tak-438, once daily (qd), compared to lansoprazole for the maintenance treatment of healed erosive esophagitis and to determine the clinical dose.


Eligibility criteria:
inclusion criteria: 1. at visit h-1 (start of the treatment period), the participants must have endoscopically confirmed erosive esophagitis of grade a to d, as defined by the la classification grading system, and the target number of participants who are clearly grade c or d is 15% or more of the total participants. 2. outpatients (including inpatient for examination) 3. participants must have successfully completed the treatment period and have endoscopically healed ee at week 2, 4, or 8 in the treatment period. endoscopically healed ee is defined as those participants who have endoscopically confirmed ee of grade o as defined by the la classification grading system. exclusion criteria: 1. participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). however, participants with schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or barrett's esophagus are allowed to be included. 2. participants who have received surgery or treatment affecting gastroesophageal reflux (cardioplasty, dilation of esophageal stenosis \[excluding schatzki's ring\], etc.), or who have a history of surgery of stomach or duodenum (excluding removal of benign polyp under endoscopy) 3. participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer (mucosal defect with white coating) within 30 days prior to visit h-1 (initiation of study drug administration). however, participants with gastric or duodenal erosions are allowed to be included. 4. participants with a previous or current history of zollinger-ellison syndrome, or other gastric acid hypersecretion disorder

Keywords: drug therapy